简介：AbstractInfectious diseases are an increasing threat to global biosafety. Vaccination is the most effective and cost-efficient method for preventing and controlling infectious diseases. The development of new vaccines is inextricably linked to the advancement of materials that serve as essential components of vaccines, such as antigens, adjuvants, and their carriers. The physicochemical and biological properties of vaccines—such as the kinetics of antigen retention and presentation—are determined by the material compositions of vaccines and carriers, affecting the overall efficacy. The sustained release of antigens prolongs their retention time in germinal centers and improves humoral immune responses. Pulsatile release that imitates clinical dosing regimens can improve patient adherence to vaccination, affording increased vaccine coverage. Herein, we review progress of materials innovation on altering vaccine release kinetics, which affects the overall vaccine efficacy, safety, and compliance.

简介：无

简介：

简介：

简介：无

简介：

简介：AbstractAnti-influenza drugs are one of the most critical pathways for control of influenza virus infection. Drugs that have been developed or are developing may function via different mechanisms, and so far, inhibitors of influenza virus polymerase are among the most promising types of drugs. Favipiravir and Baloxavir, also named T-705 and Xofluza respectively, have been approved for influenza treatment in Japan and the United States. Favipiravir effectively and selectively inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses while Baloxavir specifically targets the cap-dependent endonuclease PA of influenza viruses. These two drugs have been suggested as the first candidate drugs for influenza infection treatment, especially for strains resistant to other anti-influenza drugs. This review will focus on the pharmaceutical mechanisms and anti-influenza activity of these two drugs.

简介：客观：在食管的恶意的阻塞上学习内视镜的治疗的效果。方法：先进食道的癌症病人的64个盒子有食管的阻塞，7个盒子不能被操作，57个盒子复发了在操作以后的损害和放射治疗。阻塞都与食道的扩张器被扩大，然后用elemene乳剂注射和stent的本地化疗，或本地管理被对待被放在食道的腔。结果：阻塞与膨胀被减轻仅仅大约一个星期，而是阻塞，用用另外的治疗在膨胀以后减轻了超过三个月。在膨胀以后，然而，癌的PR在本地化疗组是大约80%CR是大约8%，PR在elemene的组是大约92%乳剂注射。结论：内视镜的治疗是为先进食道的癌症的一个有效辩解的方法。

简介：Baseduponstudiesfromrandomizedclinicaltrials,theextended(D2)lymphnodedissectionisnowrecommendedasastandardprocedureforlocaladvancedgastriccancerworldwide.However,therationalextentlymphadenectomyforlocaladvancedgastriccancerhasremainedatopicofdebateinthepastdecades.Duetothelimitationoflowmetastaticrateinpara-aorticnodes(PAN)inJCOG9501,theclinicalbenefitofD2+para-aorticnodaldissection(PAND)forpatientswithstageT4and/orstageN3disease,whichisverycommoninChinaandothercountriesexceptJapanandKorea,cannotbedetermined.Furthermore,theroleofsplenectomyforcompleteresectionofNo.10andNo.11nodeshasbeencontroversial,andhowever,thefinalresultsfromtherandomizedtrialofJCOG0110haveyettobecompleted.GastriccancerwiththeNo.14andNo.13lymphnodemetastasisisdefinedasM1stageinthecurrentversionoftheJapaneseclassification.WeproposethatD2+No.14vand+No.13lymphadenectomymaybeanoptioninapotentiallycurativegastrectomyfortumorswithapparentmetastasistotheNo.6nodesorinfiltratetoduodenum.Theexaminedlymphnodeandextranodalmetastasisaresignificantlyassociatedwiththesurvivalofgastriccancerpatients.

简介：

简介：瞄准：在先进或变形的颜色加irinotecan+/-bevacizumab调查cape-citabine的功效和安全表面的癌症病人。方法：四十六个病人与以前未经治疗，局部地进展或变形颜色表面的癌症(mCRC)在未来的开标签的阶段II试用在2001-2006之间被招募，在德国基于社区的门诊病人诊所。病人们加bevacizumab(CAPIRI十亿电伏)加irinotecan(CAPIRI)或CAPIRI收到了标准capecitabine政体每3wk。剂量减小从在>等级2毒性的情况下的第一个周期是强制的。bevacizumab的治疗选择依据见解医生。主要端点是反应和毒性，第二等的端点包括了没有前进的幸存和全面幸存。结果：在CAPIRI组对CAPRI十亿电伏组，比男病人(47%对24%)有更多的女性，并且更多的病人与作为主要肿瘤地点(5.9%对20.7%)有S字形的冒号的更少病人一起作为主要肿瘤地点(58.8%对48.2%)有冒号。等级3/4毒性比CAPIRI十亿电伏与CAPIRI是更高的：82%对58.6%。部分反应率是29.4%和34.5%，并且肿瘤控制率分别地是70.6%和75.9%。没有完全的回答被观察。中部的没有前进的幸存分别地为CAPIRI和CAPIRI十亿电伏是11.4瞬间和12.8瞬间。为CAPIRI的中部的全面幸存是15瞬间(458d)并且为CAPIRI十亿电伏24瞬间(733d)。这些差别不是统计上不同的。在CAPIRI十亿电伏，组织，二个病人在治疗以后经历了完整的第二等的肿瘤切除术，而在CAPIRI组没有盒子经历了这个过程。结论：政体很好被容忍并且在这门诊病人设置为有效肿瘤提供了生长控制。严重胃肠的毒性和thromboembolic事件是稀罕的并且如果观察从来不是致命的。

简介：Thecompressedsensing(CS)ofaccelerationdatahasbeendrawingincreasingattentioningaittelemonitoringapplication.Insuchapplication,therestillexistsomechallengingissuesincludinghighenergyconsumptionofbody-worndeviceforaccelerationdataacquisitionandthepoorreconstructionperformanceduetononsparsityofaccelerationdata.Thus,thenovelschemeofcompressivesensingofaccelerationdataisneededurgentlyforsolutionsthatarefoundtotheseissues.

简介：

简介：Inthisreview,weintensivelyfocusontheadvancesinresearchofnaturalproducts(NPs)discoverycarriedoutbydomesticscholarsinChinafrom2015through2017.Ingeneral,atotalof1811publications(1479inEnglishand332inChinese)wereaccumulatedregardingnewlyisolatedNPsfromplants,microorganisms,andmarinesources.Asaresult,277selectedpapersconcerningnaturallyoccurringcompoundswithextraordinaryframeworks,origins,andpromisingactivitieswerediscussedinthisreviewarticle,mainlyorganizedaccordingtotheirstructuralclassesandnovelties.

简介：AbstractGastric cancer, which has a high incidence and poor prognosis, remains a therapeutic challenge. Recently, neoadjuvant therapy has attracted increasing attention due to high recurrence rate and low survival rate after resection in most patients with advanced stage. Clinical trials show that neoadjuvant approaches confer a significant survival advantage for resectable locally advanced gastric cancer. The specific advantages of chemoradiotherapy compared with chemotherapy have not been clarified; optimal regimens and cycles, particularly in the preoperative setting, should be studied further; and trials aimed at determining the role of targeted and immunological therapies should be conducted.

简介：包括肠的组织变形(IM)和发育异常(Dys)评估在前列腺干细胞抗原(PSCA)和先进癌症前期的胃的损害的风险的基因多型性之间的关系的目的，基于人口的研究在Linqu被进行县，在中国的胃的癌症(GC)的一个高风险的区域。包括表面的胃炎(SG)的胃的损害的流行，长期的衰退胃炎(CAG)，IM和Dys被组织病理学说的检查决定的方法。遗传型被聚合酶链反应限制决定碎片长度多型性(PCR-RFLP)技术。IM和Dys的风险上的PSCA基因变体的效果被无条件的逻辑回归计算。结果Multivariate分析表明带PSCArs2294008CT/TT遗传型的题目与IM的增加的风险被联系(OR=1.38，95%CI=1.111.71)并且Dys(OR=1.75，95%CI=1.362.26)，特别为有H.pylori感染的题目(IM：OR=1.34，95%CI=1.051.71；Dys：OR=1.82，95%CI=1.372.42)。而且，H。pylori感染和PSCArs2294008CT/TT遗传型被观察联合提高IM的风险(OR=3.32，95%CI=2.334.71)并且Dys(OR=4.58，95%CI=2.997.04)。这研究建议了那PSCArs2294008的结论可能在GC的高风险人口之中影响IM或Dys的风险。

简介：

简介：Theuterinetetaniccontractionanduterinearterybloodflowreductionarepossiblereasonsforprimarydysmenorrhea（PD）.Inthepresentstudy,weaimedtoevaluatetheuterinerelaxanteffectandtheinfluenceonuterinearterybloodvelocityofGe-GenDecoction（GGD）,awell-knownChineseherbalformula.InfemaleICRmice,uterinecontractionwasinducedbyoxytocinexposurefollowingestradiolbenzoatepretreatment,andtheuterinearterybloodvelocitywasdetectedbyDopplerultrasound.HistopathologicalexaminationoftheuterinetissuesampleswereperformedbyH&Estaining.Exvivostudiesdemonstratedthatoxytocin,posteriorpituitary,oracetylcholineinducedcontractionsinisolatedmouseuterus.GGDinhibitedbothspontaneousandstimulatedcontractions.InvivostudydemonstratedthatGGDsignificantlyreducedoxytocin-inducedwrithingresponseswithamaximalinhibitionof87%.FurtherstudydemonstratedthatGGDnormalizedoxytocin-inducedabnormalitiesofprostaglandinsF2alpha(PGF2α)andCa2+inmice.Inaddition,injectionofoxytocininducedadecreaseinuterinearterybloodflowvelocity.PretreatmentwithGGDreversedtheoxytocinresponseonbloodflowvelocity.HistopathologicalexaminationshowedpretreatmentwithGGDalleviatedinflammationandedemaintheuteruswhencomparedwiththemodelgroup.BothexvivoandinvivoresultsindicatedthatGGDpossessedasignificantspasmolyticeffectonuterinetetaniccontractionaswellasimprovementonuterinearterybloodvelocitywhichmayinvolvePGF2αandCa2+signaling,suggestingthatGGDmayhaveaclinicpotentialinPDtherapy.

简介：AIMTheformationofadvancedglycationendproducts(AGEs)onconnectivetissueandmatrixcomponentsleadstoincreasesincollagencrosslinkingthatcontributestoaorticandmyocardialstiffnessinnormalagingandwhichoccursatanacceleratedrateindiabetes.Inthisstudy,weexaminedtheeffectsofanovelAGEsbreaker,C36,oncardiovasculardysfunctionsinexperimentaldiabeticrats.METHODSandRESULTSMaleWiatarratsweremadediabeticbyi.p.injectionof70mg/kgstreptozotocin.After12weeksofdiabetes,theanimalswererandomlydividedinto4groups(n=8-11),

简介：Gastrointestinaltoxicities(GIT),includingoralmucositis,nauseaandvomiting,anddiarrhea,arecommonsideeffectsofchemotherapyandtargetedagentsinpatientswithadvancedcolorectalcancerandpancreaticcancer.Beingoftenunderreported,itisstilldifficulttopreciselyestablishtheirburdenintermsofbothpatient’squalityoflifeandcancercarecosts.Moreover,withtheuseofmoreintensiveupfrontcombinationregimens,thefrequencyofthesetoxicitiesisrapidlygrowingwithapotentialnegativeeffectalsoonpatient’soutcome,asaresultofdosereductions,delaysorevendiscontinuationofactivetreatments.Thus,identifyingpatientsathigherriskofdevelopingGITaswellasanoptimalmanagementareparamountinordertoimprovepatient’scomplianceandoutcome.Afterthedescriptionofthemaintreatment-inducedGIT,wediscussthecurrentknowledgeonthepathophysiologyofthesesideeffectsandcommentthescalescommonlyusedtoassessandgradethem.WethenprovideacriticalupdateonGITincidencebasedontheresultsofkeyrandomizedtrialsconductedinpatientswithmetastaticcolorectalcancerandadvancedpancreaticcancer.